Cytokinetics (CYTK) Earns Buy Rating from Cowen

Cytokinetics (NASDAQ:CYTK)‘s stock had its “buy” rating reissued by research analysts at Cowen in a research note issued on Tuesday. They presently have a $11.00 price target on the biopharmaceutical company’s stock. Cowen’s price objective suggests a potential upside of 43.79% from the company’s previous close.

CYTK has been the topic of a number of other research reports. HC Wainwright set a $20.00 target price on shares of Cytokinetics and gave the company a “buy” rating in a research report on Friday, January 19th. Morgan Stanley reaffirmed an “overweight” rating and issued a $17.00 target price (down previously from $25.00) on shares of Cytokinetics in a research report on Wednesday, November 22nd. Cantor Fitzgerald cut shares of Cytokinetics from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $21.00 to $10.00 in a research report on Wednesday, November 22nd. ValuEngine cut shares of Cytokinetics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Cytokinetics in a research report on Sunday, October 29th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $16.60.

Cytokinetics (NASDAQ CYTK) opened at $7.65 on Tuesday. Cytokinetics has a 1 year low of $7.00 and a 1 year high of $17.20. The company has a debt-to-equity ratio of 0.29, a current ratio of 8.46 and a quick ratio of 7.60. The company has a market cap of $412.22, a PE ratio of -2.97 and a beta of 1.03.

Cytokinetics (NASDAQ:CYTK) last posted its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.04). Cytokinetics had a negative net margin of 172.27% and a negative return on equity of 96.95%. The company had revenue of ($0.02) million during the quarter, compared to analyst estimates of $4.83 million. equities research analysts forecast that Cytokinetics will post -1.74 EPS for the current fiscal year.

A number of large investors have recently modified their holdings of the business. MetLife Investment Advisors LLC purchased a new stake in Cytokinetics during the fourth quarter worth about $153,000. Millennium Management LLC purchased a new stake in Cytokinetics during the fourth quarter worth about $218,000. Two Sigma Investments LP increased its stake in Cytokinetics by 258.1% during the fourth quarter. Two Sigma Investments LP now owns 113,902 shares of the biopharmaceutical company’s stock worth $928,000 after purchasing an additional 82,093 shares during the period. Two Sigma Advisers LP increased its stake in Cytokinetics by 62.6% during the fourth quarter. Two Sigma Advisers LP now owns 74,800 shares of the biopharmaceutical company’s stock worth $610,000 after purchasing an additional 28,800 shares during the period. Finally, Ellington Management Group LLC purchased a new stake in Cytokinetics during the fourth quarter worth about $128,000. Institutional investors own 63.67% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Cytokinetics (CYTK) Earns Buy Rating from Cowen” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/22/cytokinetics-cytk-earns-buy-rating-from-cowen.html.

About Cytokinetics

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Analyst Recommendations for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply